The two classes of novel antidiabetic non-insulin drugs that are important for the standard-of-care treatment of T2DM are sodium-glucose loop transporter 2 inhibitors (SGLT-2i) and glucagon-like peptide 1 receptor agonists (GLP-1 RA). The gene discussed is INS; the disease is type 2 diabetes mellitus.